IP Library › Granted Patent US 12,559,527
Granted Patent B2
US 12,559,527 · App. 17/771,349 · Granted Feb 24, 2026

Compositions comprising V2 opt HIV envelopes

Inventors: Kevin O. Saunders (Durham, NC); Barton F. Haynes (Durham, NC); Bette T. Korber (Los Alamos, NM); Kshitij G. Wagh (Los Alamos, NM); Beatrice H. Hahn (Philadelphia, PA); Ronnie M. Russell (Philadelphia, PA)
Assignees: Duke University; Triad National Security, LLC; The Trustees of The University of Pennsylvania
C07K14/005A61K39/12A61P31/18C12N2740/16022C12N2740/16034C12N2740/16134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,559,527
App. No.
17/771,349
Granted
Feb 24, 2026
Kind
B2
Abstract

In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelopes with optimized V2 loop for antibody induction.

Claims (37)

1 . A recombinant HIV-1 envelope polypeptide comprising

all consecutive amino acids immediately after the signal peptide MPMGSLOPLATLYLLGMLVASVLA in SEQ ID NO: 33, 34, 35, 36, 37 or 38.

2 . A nucleic acid encoding the recombinant HIV-1 envelope polypeptide of claim 1 .

3 . A recombinant trimer comprising three identical protomers of an HIV-1 envelope polypeptide, wherein the HIV-1 envelope polypeptide comprises all consecutive amino acids immediately after the signal peptide MPMGSLOPLATLYLLGMLVASVLA in SEQ ID NO: 33, 34, 35, 36, 37 or 38.

4 . An immunogenic composition comprising the recombinant trimer of claim 3 and a carrier.

5 . An immunogenic composition comprising the nucleic acid of claim 2 and a carrier.

6 . The immunogenic composition of claim 4 , further comprising an adjuvant.

7 . The nucleic acid of claim 2 , wherein the nucleic acid is operably linked to a promoter, and wherein in certain embodiment the nucleic acid is inserted in an expression vector.

8 . A method of inducing an immune response in a subject comprising administering an immunogenic composition comprising any suitable form of the nucleic acid(s) of claim 2 and a carrier in an amount sufficient to induce an immune response.

9 . The method of claim 8 wherein the nucleic acid encodes a transmembrane.

10 . The method of claim 8 , wherein the immunogenic composition further comprises an adjuvant.

11 . The method of claim 8 , further comprising administering an agent which modulates host immune tolerance.

12 . The method of claim 8 , further comprising administering one or more additional HIV-1 immunogens to induce a T cell response.

13 . A composition comprising a nanoparticle and a carrier, wherein the nanoparticle comprises any one of the recombinant HIV-1 envelope polypeptides of claim 1 .

14 . The composition of claim 13 , wherein the nanoparticle is ferritin self-assembling nanoparticle.

15 . A composition comprising a nanoparticle and a carrier, wherein the nanoparticle comprises any one of the trimers of claim 3 .

16 . The composition of claim 15 wherein the nanoparticle is ferritin self-assembling nanoparticle.

17 . The composition of claim 15 , wherein the nanoparticle comprises multimers of the trimers.

18 . The composition of claim 15 , wherein the nanoparticle comprises 1-8 trimers.

19 . The method of claim 8 , wherein the immunogenic composition is administered as a prime.

20 . The method of claim 8 , wherein the immunogenic composition is administered as a boost.

21 . The immunogenic composition of claim 5 further comprising an adjuvant.

22 . The recombinant HIV-1 envelope of claim 1 , wherein the polypeptide is a protomer designed to form an envelope trimer.

23 . The immunogenic composition of claim 5 , wherein the nucleic acid is operably linked to a promoter, and wherein the nucleic acid is inserted in an expression vector.

24 . A method of inducing an immune response in a subject comprising administering an immunogenic composition comprising any suitable form of any one of the recombinant HIV-1 envelope polypeptides of claim 1 and a carrier in an amount sufficient to induce an immune response.

25 . The method of claim 24 , wherein the recombinant HIV-1 envelope polypeptide forms a trimer, wherein the trimer comprises three identical protomers.

26 . The method of claim 24 , wherein the immunogenic composition further comprises an adjuvant.

27 . The method of claim 24 , further comprising administering an agent which modulates host immune tolerance.

28 . The method of claim 24 , wherein the recombinant HIV-1 envelope polypeptide administered is multimerized in a liposome or nanoparticle.

29 . The method of claim 24 , further comprising administering one or more additional HIV-1 immunogens to induce a T cell response.

30 . The method of claim 24 , wherein the immunogenic composition is administered as a prime.

31 . The method of claim 24 , wherein the immunogenic composition is administered as a boost.

32 . The method of claim 28 , wherein the nanoparticle is ferritin self-assembling nanoparticle.

33 . The method of claim 25 , wherein the trimer administered is in a nanoparticle.

34 . The method of claim 33 , wherein the nanoparticle is a ferritin self-assembling nanoparticle.

35 . The method of claim 33 , wherein the nanoparticle comprises multimers of the trimers.

36 . The method of claim 33 , wherein the nanoparticle comprises 1-8 trimers.

Assignments (1)
CONFIRMATORY LICENSE Recorded Oct 31, 2022
From: TRIAD NATIONAL SECURITY, LLC
To: U.S. DEPARTMENT OF ENERGY
Reel/Frame 061592/0880 →
Continuity (2)
Provisional Application 62925173 · Oct 23, 2019
Related Publication 20220380412A1 · Dec 1, 2022
References Cited (87)
US 7951377B2 · Korber et al. · 2011 [cited by applicant]
US 9012219B2 · Kariko et al. · 2015 [cited by applicant]
US 9371511B2 · Kariko et al. · 2016 [cited by applicant]
US 10004800B2 · Haynes et al. · 2018 [cited by applicant]
US 10006007B2 · Kariko et al. · 2018 [cited by applicant]
US 20090286852A1 · Kariko et al. · 2009 [cited by applicant]
US 20130111615A1 · Kariko et al. · 2013 [cited by applicant]
US 20130197068A1 · Kariko et al. · 2013 [cited by applicant]
US 20130261172A1 · Kariko et al. · 2013 [cited by applicant]
US 20150038558A1 · Kariko et al. · 2015 [cited by applicant]
US 20160032316A1 · Weissman et al. · 2016 [cited by applicant]
US 20170043037A1 · Kariko et al. · 2017 [cited by applicant]
US 20170327842A1 · Weissman et al. · 2017 [cited by applicant]
US 20180028645A1 · Ciaramella et al. · 2018 [cited by applicant]
US 20180265848A1 · Kariko et al. · 2018 [cited by applicant]
US 20180344838A1 · Ciaramella et al. · 2018 [cited by applicant]
WO WO2013006688A2 · 2013 [cited by applicant]
WO WO2014042669A1 · 2014 [cited by applicant]
WO WO2015127108A1 · 2015 [cited by applicant]
WO WO2016176330A1 · 2016 [cited by applicant]
WO WO2017151801A1 · 2017 [cited by applicant]
WO WO2017182524A1 · 2017 [cited by applicant]
WO WO2018005558A1 · 2018 [cited by applicant]
WO WO2018075559A1 · 2018 [cited by applicant]
WO WO2018081638A1 · 2018 [cited by applicant]
WO WO2018218225A1 · 2018 [cited by applicant]
WO WO2020072169A1 · 2020 [cited by applicant]
WO WO2021081437A2 · 2021 [cited by applicant]
Andrabi, R., et al., “The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template,” Cell Reports, vol. 27, No. 8, pp. 2426-2441 and e1-e6—23 total pages (May 21, 2019). [cited by applicant]
Arnaoty, A., et al., “Reliability of the nanopheres-DNA immunization technology to produce polyclonal antibodies directed against human neogenic proteins,” Mol. Genet. Genomics, vol. 288, pp. 347-363, 17 total pages (pu… [cited by applicant]
Arnaoty, A., et al., “Novel approach for the development of new antibodies directed against transposase-derived proteins encoded by human neogenes,” Yves Bigot (ed.), Mobile Genetic Elements: Protocols and Genomic Appli… [cited by applicant]
Bamrungsap, S., et al., “Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system,” Nanomedicine, vol. 7, No. 8, pp. 1253-1271, 19 total pages (2012). [cited by applicant]
Barouch, D. H., et al., “Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys,” Nature Medicine, vol. 16, No. 3, pp. 319-323 (2010)—Author Manuscript available in PMC Sep. 1,… [cited by applicant]
Batista, F. D., et al., “B cells extract and present immobilized antigen: implications for affinity discrimination,” The EMBO Journal, vol. 19, No. 4, pp. 513-520, 8 total pages (2000). [cited by applicant]
Batista, F.D., et.al., “Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate,” Immunity 8: pp. 751-759, 9 total pages (1998). [cited by applicant]
Binley, James M., et al., “Enhancing the Proteolytic Maturation of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins,” Journal of Virology, vol. 76, No. 6, pp. 2606-2616 (Mar. 2002). [cited by applicant]
Bonsignori, M., et al., “Staged induction of HIV-1 glycan-dependent boradly neutralizing antibodies,” Sci Transl Med., vol. 9, No. 381: doi: 10.1126/scitranslmed.aai7514, pp. 1-26 (Mar. 15, 2017)—Author Manuscript avail… [cited by applicant]
Bosch, Valerie, et al., “Mutational Analysis of the Human Immunodeficiency Virus Type 1 env Gene Product Proteolytic Cleavage Site,” Journal of Virology, vol. 64, No. 5, pp. 2337-2344, 8 total pages (May 1990). [cited by applicant]
Bricault, CH.A., et al., “HIV-1 Neutralizing Antibody Signatures and Applicaton to Epitope-Trgeted Vaccine Design,” Cell Host Microbe, vol. 25, pp. 59-72 and e1-e8, 23 total pages (Jan. 9, 2019). [cited by applicant]
Cany, J., et al., “AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice,” Journal of Hepatology, vol. 54, pp. 115-121, 7 total pages (available online Aug. 26, 2010). [cited by applicant]
Center, R.J., et al., “Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface,” Journal of Virology, vol. 76, No. 15, pp. 7863-7867, 5 total pages (Aug. 2002). [cited by applicant]
Chakrabarti, B. K., et al., “Modifications of the Human Immunodeficiency Virus Envelope Glycoprotein Enhance Immunogenicity for Genetic Immunization,” Journal of Virology, vol. 76, No. 11, pp. 5357-5368, 12 total pages … [cited by applicant]
Chen, C., et al., “The site and stage of anti-DNA B-cell deletion,” Nature, vol. 373, pp. 252-255, 4 total pages (Jan. 19, 1995). [cited by applicant]
De Taeye, S. W., et al., “Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes,” Cell., vol. 163, No. 7, pp. 1702-1715 (Dec. 17, 2015)—Author Manuscript available in PMC… [cited by applicant]
Gao, F., et al., “Antigenicity and Immunogenicity of a Synthetic Human Immunodeficiency Virus Type 1 Group M Consensus Envelope Glycoprotein,” Journal of Virology, vol. 79, No. 2, pp. 1154-1163, 10 total pages (Jan. 200… [cited by applicant]
Gorman, J., et al., “Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design,” Nature Structural and Molecular Biology, vol. 23, No. 1, pp. 81-90 (Jan. 2016)—Aut… [cited by applicant]
Graham, B.S., et al., “DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial,” Public Library of Scien… [cited by applicant]
Guo, H.-G., et al., “Characterization of an HIV-1 Point Mutant Blocked in Envelope Glycoprotein Cleavage,” Virology, vol. 174, pp. 217-224, 8 total pages (accepted Sep. 29, 1989). [cited by applicant]
Haynes, B. F., et al., “B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study,” Nat. Biotechnol., vol. 30, No. 5, pp. 423-433 (2012)—Author Manuscript available in PMC May 7, 2013 (30 total p… [cited by applicant]
He, L., et al., “Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles,” Nature Communications, vol. 7, No. 12041, pp. 1-15, 15 total pages (Jun. 28, 2016). [cited by applicant]
International Search Report and Written Opinion mailed Apr. 21, 2021 by U.S Patent and Trademark Office in International Patent Application No. PCT/US2020/057205 (16 total pages). [cited by applicant]
Julien, J-P., et al., “Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens,” Proceedings of the National Academy of Sciences of the United States of Americ… [cited by applicant]
Kepler, T.B., et al., “Somatic Hypermutation in B Cells: an Optimal Cootrol Treatment,” Journal of Theoretical Biology, vol. 164, pp. 37-64, 28 total pages (accepted Jan. 14, 1993). [cited by applicant]
Kibler, K. V., et al., “Improved NYVAC-based vaccine vectors,” Public Library of Science ONE, vol. 6, No. 11: e25674, pp. 1-13, 13 total pages (Nov. 9, 2011). [cited by applicant]
Kwon, Y. D., et al., “Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env,” Nature Structural & Molecular Biology, vol. 22, No. 7, pp. 522-531, 10 total pages (Jul. … [cited by applicant]
Li, Y., et al., “Control of Expression, Glycosylation, and Secretion of HIV-1 gp120 by Homologous and Heterologous Signal Sequences,” Virology, vol. 204, No. 1, pp. 266-278, 13 total pages (accepted Jun. 23, 1994). [cited by applicant]
Li, Y., et al., “Effects of inefficient cleavage of the signal sequence of HIV-1 gp120 on its association with calnexin, folding, and intracellular transport,” Proceedings of the National Academy of Sciences of the Unit… [cited by applicant]
Liao, H. X., et al., “A group M consensus envelope glycoportein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses,” Virology 2006, vol. 353, pp. 268-282, 15 total pages (available onlin… [cited by applicant]
Liao, H.X, et al., “Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1,” Journal of Virology, vol. 87, No. 8, pp. 4185-4201, 17 t… [cited by applicant]
Liao, H.X., et al., “Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus,” Nature, vol. 496, No. 7446, pp. 469-476 (Apr. 25, 2013)—Author Manuscript available in PMC Oct. 25, 2017 (25 total pages). [cited by applicant]
Liu, M., et al., “Polyreactivity and autoreactivity among HIV-1 antibodies,” Journal of Virology, vol. 89, No. 1, pp. 784-798, 15 total pages (Jan. 2015). [cited by applicant]
Mascola, J. R., et al., “HIV-1 neutralizing antibodies: understanding nature's pathways,” Immunological Reviews, vol. 254, No. 1, pp. 225-244 (2013)—Manuscript available in PMC Jul. 1, 2014 (29 total pages). [cited by applicant]
McCune, J.M., et al., “Endoproteolytic Cleavage of gp160 Is Required for the Activation of Human Immunodeficiency Virus,” Cell, vol. 53, pp. 55-67, 13 total pages (Apr. 8, 1988). [cited by applicant]
Meffre, E., et al., “Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development,” The Journal of Clinical Investigation, vol. 108, No. 6, pp. 879-886, 8 total pages (Sep. 200… [cited by applicant]
Moody, M.A., et al., “Toll-Like Receptor 7/8 (TLR7 /8) and TLR9 Agonists Cooperate To Enhance HIV-I Envelope Antibody Responses in Rhesus Macaques,” Journal of Virology, vol. 88, No. 6, pp. 3329-3339, 11 total pages (Ma… [cited by applicant]
Parren, P.W.H.I., et al., “Antibody Neutralization-Resistant Primary Isolates of Human Immunodeficiency Virus Type 1,” Journal of Virology, vol. 72, No. 12, pp. 10270-10274, 5 total pages (Dec. 1998). [cited by applicant]
Perreau, M., et al., “DNA/NYVAC Vaccine Regimen Induces HIV-Specific CD4 and CD8 T-Cell Responses in Intestinal Mucosa,” Journal of Virology, vol. 85, No. 19, pp. 9854-9862, 9 total pages (Oct. 2011). [cited by applicant]
Poignard, P., et al., “Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.,” Journal of Virolog… [cited by applicant]
Proft, T., “Sortase-mediated protein ligation: an emerging biotechnology tool for protein modification and immobilisation,” Biotechnology Letters, vol. 32, pp. 1-10, 11 total pages (published online Sep. 1, 2009). [cited by applicant]
Ringe PR., et al., 2015, Influences on the design and purification of soluble, recombinant native-like HIV-1 envelope glycoprotein trimers, J Virol, vol. 89, No. 23 pp. 12189-12210. doi: 10.1128/JVI.01768-15, 22 total p… [cited by applicant]
Sanders, R.W., et al., “A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BGSOS SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies,” Public Library of Science Pa… [cited by applicant]
Santra, S., et al., “Mosaic Vaccines Elicit CD8+ T lymphocyte Responses in Monkeys that Confer Enhanced Immune Coverage of Diverse HIV Strains,” Nature Medicine, vol. 16, No. 3, pp. 324-328 (Mar. 2010)—Manuscript availa… [cited by applicant]
Sarzotti-Kelsoe M., et al., “Optimization and Validation of the TZM-bl Assay for Standardized Assessments of Neutralizing Antibodies Against HIV-1,” J. Immunol Methods, pp. 131-146, doi:10.1016/j.jim.2013.11.022 (Jul. 2… [cited by applicant]
Saunders, K.O., et al.,“Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models,” Cell Reports, vol. 21, pp. 3681-3690, 11 total pages (Dec. 26, 2017). [cited by applicant]
Schmohl, L., et al., “Sortase-mediated ligations for the site-specific modification of proteins,” Current Opinion in Chemical Biology, vol. 22, pp. 122-128, 7 total pages (available online Oct. 6, 2014). [cited by applicant]
Shiokawa, S., et al., “IgM Heavy Chain Complementarity-Determining Region 3 Diversity Is Constrained by Genetic and Somatic Mechanisms Until Two Months After Birth,” Journal of Immunology, vol. 162, pp. 6060-6070, 11 to… [cited by applicant]
Sliepen, K., et al., “Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity,” Retrovirology, vol. 12, No. 82, pp. 1-5, 5 total pages (2015). [cited by applicant]
Tabata, A., et al., “Development of a Sortase A-mediated Peptide-labeled Liposome Applicable to Drug-delivery Systems,” Anticancer Research, vol. 35, pp. 4411-4417, 7 total pages (accepted May 12, 2015). [cited by applicant]
Tsukiji, S., et al., “Sortase-Mediated Ligation: A Gift from Gram-Positive Bacteria to Protein Engineering,” ChemBioChem, vol. 10, pp. 787-798, 12 total pages (published online on Feb. 6, 2009). [cited by applicant]
Verkoczy, L., et al., “Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance,” Proceedings of the National Academy of Sciences of the United States o… [cited by applicant]
Verkoczy, L., et al., “Rescue of HIV-1 Broad Neutralizing Antibody-Expressing B Cells in 2F5 VH X VL Knockin Mice Reveals Multiple Tolerance Controls,” Journal of Immunology, vol. 187, pp. 3785-3797, 13 total pages (acc… [cited by applicant]
Wiehe, K., et al., “Funcitonal Relevance of Imporbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development,” Cell Host & Microbe, vol. 23, No. 6, pp. 759-765, 19 pages, (June 13, 20182018). [cited by applicant]
Yang. X., et al., “Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization,” Journal of Virology, vol. 80, No. 22, pp. 11404-11408, 5 total pages (Nov. 2006). [cited by applicant]
Yu, J.S., et al., “Recombinant Mycobacterium bovis Bacillus Calmette-Guérin Elicits Human Immunodeficiency Virus Type 1 Envelope-Specific T Lymphocytes at Mucosal Sites,” Clinical and Vaccine Immunology, vol. 14, No. 7,… [cited by applicant]
Zhang, J., et al., “Optimality of Mutation and Selection in Germinal Centers,” Public Library of Science Computational Biology, vol. 6, No. 6, pp. 1-9, e1000800, pp. 1-9 , 9 total pages (Jun. 2010). [cited by applicant]
Crooks, Emma T., et al. “Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens.” PLoS Pathogens 17.10 (2021): e1009807, 67 pages. [cited by applicant]
Nerrienet, Eric, et al. “Simian immunodeficiency virus infection in wild-caught chimpanzees from Cameroon.” Journal of virology 79.2 (2005): 1312-1319. [cited by applicant]